After showing that Pfizer (NYSE:PFE) has halted its cooperation to develop giroctocogene fitelparvovec, an experimental gene therapy for hemophilia A in adults, Sangamo Therapeutics (NASDAQ:SGMO) shares fell over 50% on Tuesday. Sangamo will recover complete development and commercialization rights for the medicine after the decision. Sangamo CEO Sandy Macrae pointed out that Pfizer had revealed positive findings from a Phase 3 study in July, implying the medication is "well-positioned for regulatory filings and potential commercialization." Macrae expressed dissatisfaction and said the business intends to "explore all options to advance the program," including looking at a new collaborative partner.
Sangamo shares remain more than 90% higher year-to-date despite the massive drop; Pfizer shares went somewhat higher during the session. Moreover, Sangamo stock is up a whopping 191% in the past six months alone, leaving broader market gains in the dust. However, the recent development is likely to have a long-term impact on the stock's price as we move into the new year.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.